| Name | ZLN024 |
| Description | ZLN024 is an activator of AMPK allosteric. ZLN024 allosterically stimulates active AMPK heterotrimers and the inactive α1 subunit truncations α1 (1-394) and α1 (1-335) but not α1 (1-312). |
| In vitro | ZLN024 allosterically stimulates active AMPK heterotrimers and the inactive α1 subunit truncations α1 (1-394) and α1 (1-335) but not α1 (1-312). It increases the activity of α1β1γ1 by 1.5-fold with an EC50 of 0.42 μM, α2β1γ1 by 1.7-fold with an EC50 of 0.95 μM, recombinant AMPK α1β2γ1 by 1.7-fold with an EC50 of 1.1 μM, and AMPK α2β2γ1 by 1.6-fold with an EC50 of 0.13 μM. |
| In vivo | C57BKS db/db mice are administered a 15 mg/kg/day dose of ZLN024 by daily gavage for 5 weeks; 250 mg/kg/day Metformin (Met) is used as a positive control. After 4 weeks of treatment, ZLN024 improves glucose tolerance, reduces fasting blood glucose by 15%, and decreases liver tissue weight, triacylglycerol, and total cholesterol content. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/ml (153.74 mM)
|
| Keywords | ZLN-024 | ZLN024 | ZLN 024 | Inhibitor | inhibit | AMPK | AMP-activated protein kinase |
| Inhibitors Related | Phenformin hydrochloride | AICAR | Doxorubicin hydrochloride | Adenosine monophosphate | Adenosine 5'-monophosphate monohydrate | Metformin | Methyl cinnamate | A-769662 | Metformin hydrochloride | Chitosan oligosaccharide | Buformin hydrochloride | HTH-01-015 |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Glutamine Metabolism Compound Library | Hematonosis Compound Library | Neuroprotective Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Neuronal Differentiation Compound Library |
United States
